Date and Time:  **Tuesday 8\textsuperscript{th} and Wednesday 9\textsuperscript{th} March 2011 (Time: 10:00-16:00)**

Minutes: Confirmed

**Guideline Development Group Meeting**  Lower limb peripheral arterial disease

**Meeting 5**

**Place:**  
*Boardroom, National Clinical Guideline Centre, 180 Great Portland Street, London*

**Present:**  
Jonathan Michaels (Chair)  
Barry Atwood  
Andrew Beech (Present for agenda items 12-17)  
Sarah Bermingham  
Andrew Bradbury  
Jill Cobb (Present for agenda item 14)  
Duncan Ettles  
Michael Flynn  
Martin Fox  
Bernard Higgins (Present for agenda items 8-17)  
Kate Kelley  
Ammy Lam  
Jen Layden  
Peter Maufe  
Ricky Mullis  
Robbie Pitcher  
Laura Sawyer (Present for agenda item 10)  
Anita Sharma  
Cliff Shearman  
Katrina Sparrow  
Hazel Trender  
Raman Uberoi

**In attendance:**

<table>
<thead>
<tr>
<th>NICE Staff:</th>
<th>Guideline Commissioning Manager</th>
</tr>
</thead>
<tbody>
<tr>
<td>Claire Turner</td>
<td></td>
</tr>
</tbody>
</table>

**Observers:**

<table>
<thead>
<tr>
<th>Caroline Hatchett (Tuesday 8\textsuperscript{th} March 2011)</th>
<th>Project Manager/Research Fellow, National Clinical Guideline Centre</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Maggie Westby (Wednesday 9\textsuperscript{th} March 2011)</th>
<th>Clinical Effectiveness Lead, National Clinical Guideline Centre</th>
</tr>
</thead>
</table>

**Notes**
Notes

1. The Chair welcomed the group to the first day of the fifth meeting of this GDG. Apologies were received from Andrew Beech for the 8th March. The Chair asked all GDG members to declare any relevant conflicts of interest. All declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interest in the development of this guideline.

2. The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.

3. The Chair introduced the Senior Project Manager/Research Fellow at NCGC, Jen Layden, who presented PAD classification systems, and took questions from the group. The GDG discussed the issues presented in relation to this guideline. The Chair thanked JL for her presentation.

4. The Chair introduced Senior Research Fellow at NCGC, Katrina Sparrow, who presented on GRADE, and took questions from the group. The GDG discussed the issues presented in relation to this guideline. The Chair thanks KS for her presentation.

5. The Chair introduced the Senior Project Manager/Research Fellow at NCGC, Jen Layden, who presented the clinical effectiveness evidence for autologous vein compared to prosthetic grafting for the treatment of PAD, and took questions from the group. The GDG discussed the issues presented in relation to this guideline. The Chair thanked JL for her presentation.

6. The Chair introduced the Senior Research Fellow, Katrina Sparrow, who presented network meta-analysis, and took questions from the group. The GDG then discussed the issues presented in relation to this guideline. The Chair thanked KS for her presentation.

7. The GDG discussed issues relating to quality of life and walking distance as measurements of intervention success in PAD.

8. The Chair introduced the Senior Research Fellow at NCGC, Katrina Sparrow, who presented the clinical evidence on vasoactive drugs compared to exercise therapy, angioplasty and stents, and took questions from the group. The GDG then discussed the issues presented in relation to this guideline. The Chair thanked KS for her presentation.

9. The Chair introduced the Research Fellow at NCGC, Robert Pitcher, who presented the clinical evidence on best medical treatment compared to exercise therapy, angioplasty and stents, and took questions from the group. The GDG then discussed the issues presented in relation to this guideline. The Chair thanked RP for his presentation.

10. The Chair introduced the Health Economist at NCGC, Sarah Bermingham, who presented on baseline risks for the health economics model, and took questions from the group. The GDG discussed the issues presented in relation to this guideline. The Chair thanked SB for her presentation.

11. The Chair provided a recap on the day and overview of day two agenda. The Chair closed the meeting and thanked everyone for attending.

Notes - Wednesday 9th March 2011 – Day two

12. The Chair welcomed the group to the second day of the fifth meeting and provided a recap of the first day and an overview of the agenda.

13. The Chair introduced the Senior Project Manager/Research Fellow at NCGC, Jen Layden, who presented on producing a NICE guideline, and took questions from the
Notes

The GDG discussed the issues presented in relation to this guideline. The Chair thanked JL for her presentation.

14. The Chair introduced the Senior Project Manager/Research Fellow at NCGC, Jen Layden, and Senior Research Fellow, Katrina Sparrow, who presented on future guideline questions and protocols, and took questions from the group. The GDG discussed the issues presented in relation to this guideline. The Chair thanked JL and KS for their presentations.

15. The Chair introduced the Senior Research Fellow, Katrina Sparrow, and Health Economist, Sarah Bermingham, who provided a recap on the following clinical and cost effectiveness evidence reviews and took questions from the group on:

- Angioplasty versus stenting for the treatment of PAD
- Bare metal compared to drug eluting stents for the treatment of PAD
- Angioplasty versus surgery for the treatment of PAD

The GDG discussed the issues presented in relation to this guideline. The Chair thanked KS and SB for their presentations.

16. The Chair introduced the Health Economist, Sarah Bermingham, who presented on the health economics model, and took questions from the group. The GDG discussed the issues presented in relation to this guideline. The Chair thanked SB for her presentation.

17. The Chair closed the meeting and thanked everyone for attending.

Date, time and venue of the next meeting

Tuesday 12th April 2010 at National Clinical Guideline Centre, 5th Floor, Great Portland Street, London W1W 5QZ.